It has been previously shown that expression of a constitutively active TGFβ type I receptor (ALK5-TD) inhibits leukemic proliferation of MDS/AML cells with concurrent ASXL1 and SETBP1 mutations. The gene discussed is SETBP1; the disease is myelodysplastic syndrome.